Campos Débora, Goméz-García Ricardo, Oliveira Diana, Madureira Ana Raquel
CBQF-Centro de Biotecnologia e Química Fina, Laboratório Associado, Escola Superior de Biotecnologia, Universidade Católica Portuguesa, Porto, Portugal.
Amyris Bio Products Portugal, Unipessoal Lda, Porto, Portugal.
Gut Microbiome (Camb). 2021 Dec 28;3:e1. doi: 10.1017/gmb.2021.5. eCollection 2022.
The oral delivery of compounds associated with diet or medication have an impact on the gut microbiota balance, which in turn, influences the physiologic process. Several reports have shown significant advances in clarifying the impact, interactions and outcomes of oral intake of nanoparticles and the human gut. These interactions may affect the bioavailability of the delivered compounds. In addition, there is a considerable breakthrough in the development of antimicrobial nanoparticles for intestinal pathogenic bacteria. Several fermentation and models have been developed throughout the years and were used to test these systems. The methodologies and studies carried out so far on the modulation of human and animal gut microbiome by oral delivery nanosized materials were reviewed. Overall, the available studies mimic the real physiological events enabling to select the best production conditions of nanoparticulate systems in a preliminary stage of research. On the other hand, animal studies can be used to access the dosage effect, safety and correlation between haematological, biochemical and symptoms, with gut microbiota groups and metabolites.
与饮食或药物相关的化合物经口服给药会影响肠道微生物群平衡，进而影响生理过程。一些报告显示，在阐明纳米颗粒口服摄入对人体肠道的影响、相互作用和结果方面取得了重大进展。这些相互作用可能会影响所递送化合物的生物利用度。此外，用于肠道病原菌的抗菌纳米颗粒的开发也有了相当大的突破。多年来已经开发了几种发酵和模型，并用于测试这些系统。本文综述了迄今为止在通过口服递送纳米材料调节人和动物肠道微生物组方面所开展的方法和研究。总体而言，现有研究模拟了真实的生理事件，有助于在研究的初步阶段选择纳米颗粒系统的最佳生产条件。另一方面，动物研究可用于了解剂量效应、安全性以及血液学、生化指标和症状与肠道微生物群组和代谢物之间的相关性。
